You’ll wonder how you ever treated acromegaly before PALSONIFY
The first and only once-daily oral with biochemical and symptom control in adults with acromegaly1*
First line1
Approved for treatment-naïve patients and patients switching from iSRLs
Fast acting1
Lowered IGF-1 in 2 to 4 weeks
Reduces symptom severity1†
Reduced the severity of common acromegaly symptoms
Acromegaly control. Finally, in a pill.1
- *PALSONIFY is approved for the treatment of adults with acromegaly who had an inadequate response to surgery and/or for whom surgery is not an option.1
- †PALSONIFY demonstrated numerically lower severity of symptom scores associated with acromegaly vs placebo, as measured by a patient-reported symptom severity tool.1
- IGF-1=insulin-like growth factor 1; iSRLs=injected somatostatin receptor ligands.
MOA AND DOSING
Designed for SST2 specificity and oral administration1
PALSONIFY is the first and only nonpeptide SST2-selective agonist in a
- MOA=mechanism of action; SST2=somatostatin receptor subtype 2.
Megan,
taking PALSONIFY
EFFICACY AND SAFETY
Acromegaly control across a range of patients1
In patients switching from iSRLs and those who were biochemically uncontrolled, including treatment naïve, PALSONIFY provided rapid, reliable, and sustained biochemical and symptom control—all with a low discontinuation rate.1,3
PALSONIFY national broadcast
The Only Once-Daily Acromegaly Treatment
Listen to experts in endocrinology discuss clinical evidence and insights on PALSONIFY for the treatment of acromegaly.
